Clinical Scenarios Demonstrating Value of NGS Using Rapid, Targeted Panel and/or More Comprehensive Approaches for Oncology Biomarker Testing of Specimens.
Panel Discussion: Bridging the Gaps Towards Implementing Minimal Residual Disease in Clinical Practice – A Collaborative View Across the Healthcare Ecosystem
Overcoming Challenges in Congenital CMV Screening: Optimizing Laboratory Practices
Location: 205 - 207, Level 2
Hosted By
3:00 PM - 3:50 PM PST
Same-Day Molecular Testing Results from Cytology Specimens: The Next Frontier of Rapid On-Site Evaluation? Optimizing Small Biopsy Workflows with Idylla™
(G064) INT2GRATE Oncology Consortium: A Novel Variant Evidence Framework for Cancer Syndromes and Data-Sharing Platform for Integrated Germline and Tumor Variants
(I015) Application and Lessons Learned from Curating 100 Somatic Cancer Variants Using the ClinGen/CGC/VICC Guidelines in a Pediatric Hospital Setting.
Genomic Analysis as a Precision Tool for Daily Diagnostic Challenges: First Case Report Showing Definitive Molecular Evidence for Distant Drop Metastasis of Colonic Adenocarcinoma
Location: 118 - 120, Level 1
Case Presenter: Jiejun Wu, MD, PhD – University of California, San Francisco
7:15 AM - 7:30 AM PST
Navigating the Challenges of Identifying the Causative CIC::DUX4 Gene Fusion Using Whole Transcriptome RNA Sequencing
Location: 118 - 120, Level 1
Case Presenter: Elan Hahn, MD FRCPC – Mount Sinai Hospital; University of Toronto; University of Pittsburgh Medical Center
7:30 AM - 7:45 AM PST
Distinct Atypical Meningiomas Hiding in Plain Sight, Out SMARC’d by SMARCB1
Laboratory Considerations for the Incidental Detection of Acquired Variants in Germline Genetic Testing
Location: 109 & 110, Level 1
Breakout Speaker: Josh Deignan, PhD (he/him/his) – Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA,
Inherited Conditions
CE Credit: NOT CME/CMLE
11:15 AM - 11:45 AM PST
Considerations for the Evaluation of Acquired Variants in the Germline Genetic Testing
Location: 109 & 110, Level 1
Breakout Speaker: Elizabeth Chao, MD, FACMG (she/her/hers) – Division of Genetic and Genomic Medicine, Department of Pediatrics, University of California, Irvine, CA
Inherited Conditions
CE Credit: NOT CME/CMLE
10:15 AM - 11:45 AM PST
Molecular at Home and Point of Care Testing for Infectious Diseases
Empowering Tomorrow's Molecular Pathologists: Leveraging Publicly Available Datasets, Machine Learning, and Online Knowledge Bases for Training and Research
Location: 202- 204, Level 2
11:45 AM - 1:15 PM PST
Technologist Networking Luncheon
Location: 205 - 207, Level 2
12:00 PM - 12:30 PM PST
Innovation Spotlight
12:00 PM - 12:30 PM PST
Accelerate OGM Insights: Supercharge Your OGM Workflow to explore more SV discovery
Location: Innovation Spotlight Stage #1
Innovation Spotlight Speaker: Alex Hastie – Bionano
Clinical Cancer Whole Exome and Transcriptome Sequencing: Lessons learned over 10 years and future outlook
Location: 220 - 222, Level 2
Breakout Speaker: Susan Hsiao, MD, PhD – Columbia University Irving Medical Center
Oncology
CE Credit: 1.5
2:00 PM - 2:45 PM PST
Clinical Validation and Implementation of Somatic Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) for Solid Tumors and Hematopoietic Neoplasms.
Advances in Characterizing Structural Chromosomal Alterations: Utility of Optical Genome Mapping and Long Read Sequencing in Hematopoietic Cancers and the Germline Genome
Co-Moderator (Early Career): Eric McGinnis, MD (he/him/his) – Vancouver General Hospital / University of British Columbia
Oncology
CE Credit: 1.5
10:15 AM - 11:45 AM PST
Advances in Characterizing Structural Chromosomal Alterations: Utility of Optical Genome Mapping and Long Read Sequencing in Hematopoietic Cancers and the Germline Genome
2024 CAP/IASLC/AMP Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline Update
Working Group Moderator: Susan Hsiao, MD, PhD – Columbia University Irving Medical Center
Oncology
1:15 PM - 2:15 PM PST
2024 CAP/IASLC/AMP Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline Update
Location: 301 - 305, Level 3
Working Group Moderator: Susan Hsiao, MD, PhD – Columbia University Irving Medical Center
Oncology
1:15 PM - 2:15 PM PST
2024 CAP/IASLC/AMP Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline Update
(H036) FNIH MRD in AML Biomarkers Consortium: Evaluation of Methods for Detection of FLT3 Internal Tandem Duplication Measurable Residual Disease in Acute Myeloid Leukemia
(ID007) Adding Infectious Disease Samples to a Cancer Next-Generation Sequencing Workflow Decreases Costs and Increases Efficiency of Whole-Genome Sequencing for Pathogen Identification and Surveillance
(ST014) The Utilization of Whole Transcriptome Sequencing to Analyze Downstream Expression of Biologically Significant Transcripts of Potentially Oncogenic Fusion Products, for Clinical Practice
(ST077) Comprehensive Assessment of Solid Tumors by Optical Genome Mapping and Next-Generation Sequencing Reveals Cryptic Structural Variants of Diagnostic, Prognostic, and Therapeutic Significance